港股異動 | 開拓藥業-B(9939.HK)大幅反彈13% 此前最大回撤超50%
格隆匯11月9日丨昨日創階段低價的開拓藥業-B(9939.HK)大幅拉昇漲13%,此前自高位最大回撤超50%,現報44.4港元,總市值172億港元。日前公司ALK-1單抗聯合康寧傑瑞KN046治療晚期或難治性實體腫瘤臨牀試驗完成首例患者給藥。目前ALK-1單抗聯合療法在ASCO GI 2021上公佈的中國台灣臨牀試驗數據顯示療效令人鼓舞且安全性良好,其中客觀緩解率(ORR)達到40%。另外,公司AR拮抗劑普克魯胺,在巴西完成的臨牀試驗顯示療效顯著,並已於7月獲巴拉圭緊急使用授權,目前正在開展住院新冠患者的III期全球多中心臨牀試驗。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.